Scholar Rock

CAMBRIDGE, MA · Founded 2012 · Biotech · Public

Novel biopharmaceutical therapeutics targeting protein signaling pathways

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · scholarrock.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Founded
2012
Latest Form D
$36.3M, Jan 2016
Total capital
$36.3M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$36.3M
1 Form D · last Jan 2016
130 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
19
21 pending · first 2022
Rank in peer group#53 of 1449

Capital timeline

2016FEDERAL ↑EQUITY ↓Cumulative $36.3M1st Form D$36.3M
2016FEDERAL ↑EQUITY ↓Cumulative $36.3M1st Form D$36.3M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$36.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#53 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Amir NashatDirectorNamed in SEC Form D filings
  • Katrine BosleyDirectorNamed in SEC Form D filings
  • Kristina BurowDirectorNamed in SEC Form D filings
  • Michael GilmanDirectorNamed in SEC Form D filings
  • Nagesh MahanthappaExecutive Officer, DirectorNamed in SEC Form D filings
  • Timothy SpringerDirectorNamed in SEC Form D filings

What it has protected

USPTO · 19 granted of 40
  • New patentTGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOFUSPTOUS 12,753,226
  • PendingMethods For Inhibiting Myostatin Activation By Administering Anti-pro/latent Myostatin AntibodiesUSPTOApplication 19427341
  • PendingLtbp Complex-specific Inhibitors Of Tgf-beta 1 And Uses ThereofUSPTOApplication 19235027
Show all 40 patent records
  • Liquid BioScience, Inc.Similar federal contract value in Biotech · null in contracts
  • Earli Inc.Similar federal contract value in Biotech · null in contracts
  • Bugworks Research, Inc.Similar federal contract value in Biotech · null in contracts
  • SeaStar Medical, Inc.Similar federal contract value in Biotech · null in contracts
  • SynthorxSimilar federal contract value in Biotech · null in contracts
  • Contineum TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .